BioLineRx (NASDAQ: BLRX) posts 2025 loss improvement and advances GLIX1, motixafortide

Rhea-AI Filing Summary

BioLineRx Ltd. reported audited 2025 results and highlighted progress in its oncology and rare disease pipeline. Total revenues fell to $1,180 thousand in 2025 from $28,940 thousand in 2024, reflecting a sharp decline in license and product revenues. The loss attributable to owners narrowed to $1,175 thousand, versus $9,221 thousand in 2024, as operating loss decreased and non‑operating income supported results.

At December 31, 2025, cash and cash equivalents were $3,250 thousand and short-term deposits were $17,626 thousand, with total assets of $40,905 thousand and total equity of $23,345 thousand. Management expects to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of March 2026 and continues a Phase 2b motixafortide trial in metastatic pancreatic cancer, alongside commercialization of APHEXDA for stem cell mobilization in multiple myeloma.

Insights

Biotech equity analyst

2025 revenue dropped sharply, but losses narrowed and the pipeline advanced.

BioLineRx showed a major top-line swing, with total revenues declining to $1,180 thousand in 2025 from $28,940 thousand in 2024, mainly due to lower license and product revenue. Despite this, operating loss improved to $10,287 thousand, and loss attributable to owners shrank to $1,175 thousand, supported by $8,077 thousand in non‑operating income.

The balance sheet at December 31, 2025 shows cash and cash equivalents of $3,250 thousand and short-term deposits of $17,626 thousand, with total liabilities of $17,560 thousand and equity of $23,345 thousand. This reflects prior equity financings and the addition of a $6,000 thousand intangible asset from the GLIX1 collaboration.

Strategically, the company plans to initiate a Phase 1/2a GLIX1 glioblastoma trial by the end of March 2026 and continues the CheMo4METPANC Phase 2b motixafortide trial in metastatic pancreatic cancer, with a prespecified interim/futility analysis expected in 2026. Commercial performance of APHEXDA, future clinical readouts for GLIX1 and motixafortide, and the evolution of cash balances from the 2025 base will be key factors shaping future updates.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On March 23, 2026, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: March 23, 2026

Exhibit 1

For Immediate Release

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM)

by end of this month -

- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer

treatments by targeting DNA damage response mechanisms -

- Management to host conference call today, March 23, at 8:30 am EDT -

TEL AVIV, Israel, March 23, 2026 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.

“Since our last quarterly update, we have been working diligently to move forward with a Phase 1/2a first-in-human clinical trial of GLIX1 in glioblastoma, and I am pleased to report that we expect to initiate the study by the end of this month, with the commencement of patient enrollment shortly thereafter,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “GLIX1, the lead asset that we acquired through our collaboration with Hemispherian, is a unique molecule with a novel mechanism of action that targets the DNA repair mechanism in cancer cells and has demonstrated compelling efficacy in numerous pre-clinical models, excellent blood-brain-barrier penetration and a favorable safety profile in toxicology studies. We are eager to establish the safety, recommended dose and proof-of-concept in order to advance this promising candidate through an efficient development pathway.

“In parallel, we continue to conduct pre-clinical activities in support of further development of GLIX1 in additional cancer indications with high unmet needs, and, separately, we are also conducting studies to further investigate and affirm the potential synergistic effect of GLIX1 in combination with PARP inhibitors, as we work to maximize the value of the GLIX1 opportunity.

“In metastatic pancreatic cancer, enrollment has accelerated in the ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide, which is being led by Columbia University and supported by both Regeneron and BioLineRx, and we continue to anticipate that a prespecified interim/futility analysis will read out in 2026. We believe PDAC represents another opportunity to introduce a much-needed new treatment option to patients suffering from a very challenging tumor type, while creating sustained value for our company,” Mr. Serlin concluded.

Corporate Updates

• Announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent covering GLIX1 for cancers in which cytidine deaminase (CDA) is not over-expressed beyond a specific threshold, estimated to be 90% of all cancers.

o Patent preserves BioLineRx’s ability to evaluate GLIX1 in other cancers beyond glioblastoma, including both hematological and solid tumor cancer types.

o Patent further broadens and strengthens GLIX1’s patent protection until 2040, with a possible patent-term extension of up to five years.

Financial Updates

• With $20.9 million on its balance sheet as of December 31, 2025, BioLineRx is maintaining its cash runway guidance into the first half of 2027.

Clinical Updates

GLIX1

• On track to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of the month.

o Three renowned academic centers are planned to participate in this clinical trial: Northwestern University, led by Dr. Roger Stupp and Dr. Ditte Primdahl, NYU Langone Health, led by Dr. Alexandra M. Miller and Moffit Cancer Center, led by Dr. Patrick Grogan.

o The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.

o The Phase 2a expansion part of the trial is planned to include various population cohorts, including GBM (newly diagnosed and/or recurrent), as well as additional cancers with/without standard of care (e.g., PARP inhibitors). These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for rapid and effective advanced clinical development.

• Pre-clinical activities in support of clinical development for GLIX1 in additional cancer indications are ongoing.

Motixafortide

Pancreatic Ductal Adenocarcinoma (mPDAC)

• Enrollment has accelerated in the CheMo4METPANC Phase 2b clinical trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx. The trial is evaluating motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapy (gemcitabine and nab-paclitaxel).

o A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.

Sickle Cell Disease (SCD) & Gene Therapy

• Announced that a poster featuring final results from a Phase 1 clinical trial (NCT05618301) evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in December.

• A second SCD study, sponsored by St. Jude Children's Research Hospital, continues to enroll patients. The study is a multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ HSCs for gene therapies for patients with SCD (NCT06442761).

APHEXDA Performance Update

• For the full-year 2025, APHEXDA sales were $6.7 million, which provided royalty revenue to the Company of $1.2 million.

Financial Results for the Year ended December 31, 2025

• Revenues for the year ended December 31, 2025 were $1.2 million reflecting the royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. Total revenues in 2025 are not comparable to the same period in 2024, which primarily reflect a portion of the up-front payment received by the Company under the Gloria License Agreement and a milestone payment achieved under the Gloria License Agreement, which collectively amounted to $15.0 million, as well as the up-front payment received under the Ayrmid License Agreement and $6.0 million of net revenues from product sales of APHEXDA in the United States.

• Cost of revenues for the year ended December 31, 2025 were $0.2 million, compared to cost of revenues of $9.3 million for the year ended December 31, 2024. The cost of revenues in 2025 reflects sub-license fees on royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. The cost of revenues in 2024 primarily reflects the amortization of intangible assets, sub-license fees on the up-front payment received for the Ayrmid License Agreement, sub-license fees accrued on a milestone payment recorded under the Gloria License Agreement, as well as royalties on net product sales of APHEXDA in the U.S. and cost of goods sold on product sales.

• Research and development expenses for the year ended December 31, 2025 were $8.1 million, a decrease of $1.1 million, or 11.5%, compared to $9.2 million for the year ended December 31, 2024. The decrease resulted primarily from lower expenses related to motixafortide due to the out-licensing of U.S. rights to Ayrmid, as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount, offset by expenses related to initiation of the GLIX1 project.

• There were no sales and marketing expenses for the year ended December 31, 2025, compared to $23.6 million for the year ended December 31, 2024. The decrease resulted from the shutdown of U.S. commercial operations in the fourth quarter of 2024 following the Ayrmid license agreement.

• General and administrative expenses for the year ended December 31, 2025 were $3.1 million, a decrease of $3.2 million, or 50.3%, compared to $6.3 million for the year ended December 31, 2024. The decrease resulted primarily from the reversal of a provision for doubtful accounts following receipt of an overdue milestone payment from Gloria, as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount, and a decrease in a number of general and administrative expenses.

• Non-operating income (expenses) for the years ended December 31, 2025 and 2024 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, as a result of changes in its share price, offset by warrant offering expenses.

• Net financial income for the year ended December 31, 2025 was $0.2 million, compared to net financial expenses of $7.3 million for the year ended December 31, 2024. Net financial income for 2025 relates to investment income earned on bank deposits and gains on foreign currency (primarily NIS) cash balances due to the appreciation of the NIS against the U.S. dollar during the period, partially offset by interest paid on loans. Net financial expenses for 2024 primarily relate to interest paid on loans, which increased in 2024 due to a one-time $4.0 million charge to interest expense in connection with the November 2024 amendment to loan agreement with BlackRock, partially offset by investment income earned on bank deposits.

• Net loss for the year ended December 31, 2025 was $2.0 million, compared to $9.2 million for the year ended December 31, 2024.

• As of December 31, 2025, the Company had cash, cash equivalents, and short-term bank deposits of $20.9 million, sufficient to fund operations, as currently planned, into the first half of 2027.

A copy of the Company's annual report on Form 20-F for the year ended December 31, 2025 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on the Company's investor relations website at https://ir.biolinerx.com. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request at IR@biolinerx.com.

Conference Call and Webcast Information

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until March 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company’s lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial is expected to initiate in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.  

Forward Looking Statement

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the expectations with regard to clinical trials of motixafortide and GLIX1, expected timing of clinical readouts, the expected cash runway, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx’s preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx’s receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third-party payors; BioLineRx’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx’s collaborators to execute on their development and commercialization plans; BioLineRx’s ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx’s is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx’s industry; BioLineRx’s ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx’s business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

United States

Irina Koffler

LifeSci Advisors, LLC

IR@biolinerx.com

Israel

Moran Meir

LifeSci Advisors, LLC

moran@lifesciadvisors.com

BioLineRx Ltd.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

		December 31,
		2024				2025
		in USD thousands
Assets
CURRENT ASSETS
Cash and cash equivalents			10,436				3,250
Short-term bank deposits			9,126				17,626
Trade receivables			2,476				46
Prepaid expenses			443				201
Other receivables			1,478				410
Inventory			3,145				2,148
Total current assets			27,104				23,681
NON-CURRENT ASSETS
Property and equipment, net			386				160
Right-of-use assets, net			967				696
Intangible assets, net			10,449				16,368
Total non-current assets			11,802				17,224
Total assets			38,906				40,905
Liabilities and equity
CURRENT LIABILITIES
Current maturities of long-term loan			4,479				4,479
Accounts payable and accruals:
Trade			5,583				3,493
Other			3,131				1,743
Current maturities of lease liabilities			522				234
Warrants			1,691				2,174
Total current liabilities			15,406				12,123
NON-CURRENT LIABILITIES
Long-term loan, net of current maturities			8,958				4,460
Lease liabilities			1,081				977
Total non-current liabilities			10,039				5,437
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities			25,445				17,560
EQUITY
Equity attributable to owners of the Company:
Ordinary shares			38,097				73,428
Share premium			353,693				327,584
Warrants			5,367				3,686
Capital reserve			17,547				15,916
Other comprehensive loss			(1,416	)			(1,416	)
Accumulated deficit			(399,827	)			(401,002	)
Total equity attributable to owners of the Company			13,461				18,196
Non-controlling interest			-				5,149
Total equity			13,461				23,345
Total liabilities and equity			38,906				40,905

BioLineRx Ltd.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

		Year ended December 31,
		2023				2024				2025
		in USD thousands
REVENUES:
License revenues			4,610				22,917				1,180
Product sales, net			190				6,023				-
Total revenues			4,800				28,940				1,180
COST OF REVENUES			(3,692	)			(9,263	)			(230	)
GROSS PROFIT			1,108				19,677				950
RESEARCH AND DEVELOPMENT EXPENSES			(12,519	)			(9,149	)			(8,093	)
SALES AND MARKETING EXPENSES			(25,270	)			(23,605	)			-
GENERAL AND ADMINISTRATIVE EXPENSES			(6,310	)			(6,321	)			(3,144	)
IMPAIRMENT OF INTANGIBLE ASSETS			(6,703	)			(1,010	)			-
OPERATING LOSS			(49,694	)			(20,408	)			(10,287	)
NON-OPERATING INCOME (EXPENSES), NET			(10,819	)			18,435				8,077
FINANCIAL INCOME			2,068				1,871				1,464
FINANCIAL EXPENSES			(2,169	)			(9,119	)			(1,280	)
LOSS AND COMPREHENSIVE LOSS			(60,614	)			(9,221	)			(2,026	)
ATTRIBUTION OF LOSS AND COMPREHENSIVE LOSS
To owners of the Company			(60,614	)			(9,221	)			(1,175	)
To non-controlling interests			-				-				(851	)
			(60,614	)			(9,221	)			(2,026	)

		in USD
LOSS PER ORDINARY SHARE – BASIC AND DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY			(0.06	)			(0.01	)			(0.00	)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE			963,365,525				1,198,107,761				2,465,272,604

BioLineRx Ltd.

STATEMENTS OF CHANGES IN EQUITY

		Equity attributable to owners of the Company
		Ordinary shares								Share premium				Warrants				Capital reserve				Other comprehensive loss				Accumulated deficit				Non-controlling interest				Total
		in shares 000’s				in USD thousands
BALANCE AT JANUARY 1, 2023			922,959				27,100				338,976				1,408				14,765				(1,416	)			(329,992	)			-				50,841
CHANGES IN 2023:
Issuance of share capital, net			124,955				3,242				10,847				-				-				-				-				-				14,089
Warrants exercised			38,182				1,000				5,559				-				-				-				-				-				6,559
Employee stock options exercised			493				13				45				-				(31	)			-				-				-				27
Employee stock options expired			-				-				55				-				(55	)			-				-				-				-
Share-based compensation			-				-				-				-				2,321				-				-				-				2,321
Comprehensive loss for the year			-				-				-				-				-				-				(60,614	)			-				(60,614	)
BALANCE AT DECEMBER 31, 2023			1,086,589				31,355				355,482				1,408				17,000				(1,416	)			(390,606	)			-				13,223
CHANGES IN 2024:
Issuance of share capital, pre-funded warrants and warrants, net			174,322				4,712				(3,060	)			6,650				-				-				-				-				8,302
Pre-funded warrants exercised			74,989				2,009				682				(2,691	)			-				-				-				-				-
Employee stock options exercised			770				21				50				-				(49	)			-				-				-				22
Employee stock options expired			-				-				539				-				(539	)			-				-				-				-
Share-based compensation			-				-				-				-				1,135				-				-				-				1,135
Comprehensive loss for the year			-				-				-				-				-				-				(9,221	)			-				(9,221	)
BALANCE AT DECEMBER 31, 2024			1,336,670				38,097				353,693				5,367				17,547				(1,416	)			(399,827	)			-				13,461
CHANGES IN 2025:
Issuance of share capital, pre-funded warrants and warrants, net			978,340				27,273				(22,260	)			501				-				-				-				-				5,514
Pre-funded warrants exercised			295,804				8,058				(5,876	)			(2,182	)			-				-				-				-				-
Employee stock options expired			-				-				2,027				-				(2,027	)			-				-				-				-
Share-based compensation			-				-				-				-				396				-				-				-				396
Non-controlling interest			-				-				-				-				-				-				-				6,000				6,000
Comprehensive loss for the year			-				-				-				-				-				-				(1,175	)			(851	)			(2,026	)
BALANCE AT DECEMBER 31, 2025			2,610,814				73,428				327,584				3,686				15,916				(1,416	)			(401,002	)			5,149				23,345

BioLineRx Ltd.

CONSOLIDATED STATEMENTS OF CASH FLOWS

		Year ended December 31,
		2023				2024				2025
		in USD thousands
CASH FLOWS - OPERATING ACTIVITIES
Loss			(60,614	)			(9,221	)			(2,026	)
Adjustments required to reflect net cash used in operating activities (see appendix below)			38,006				(34,652	)			(6,048	)
Net cash used in operating activities			(22,608	)			(43,873	)			(8,074	)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits			(47,588	)			(26,350	)			(36,644	)
Maturities of short-term deposits			49,329				55,778				28,126
Purchase of property and equipment			(116	)			(53	)			(25	)
Purchase of intangible assets			(181	)			(1	)			(2	)
Net cash provided by (used in) investing activities			1,444				29,374				(8,545	)
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital, pre-funded warrants and warrants, net of issuance costs			14,089				16,357				13,894
Exercise of warrants			2,928				-				-
Employee stock options exercised			27				22				-
Proceeds from long-term loan, net of issuance costs			-				19,223				-
Repayments of loan			(1,543	)			(14,433	)			(4,498	)
Repayments of lease liabilities			(445	)			(511	)			(512	)
Net cash provided by financing activities			15,056				20,658				8,884
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			(6,108	)			6,159				(7,735	)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR			10,587				4,255				10,436
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS			(224	)			22				549
CASH AND CASH EQUIVALENTS - END OF YEAR			4,255				10,436				3,250

BioLineRx Ltd.

CONSOLIDATED STATEMENTS OF CASH FLOWS

		Year ended December 31,
		2023				2024				2025
		in USD thousands
APPENDIX
Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization			1,384				4,065				523
Loss on disposal of property and equipment			-				-				25
Exchange differences on cash and cash equivalents			224				(22	)			(549	)
Fair value adjustments of warrants			11,054				(18,965	)			(8,599	)
Share-based compensation			2,321				1,135				396
Interest and exchange differences on short-term deposits			15				185				18
Interest on loan			1,148				(1,126	)			-
Warrant issuance costs			-				669				702
Exchange differences on lease liabilities			(42	)			(31	)			177
Intangible assets impairment			6,703				1,010				-
Loss on abandonment of right-of-use asset			-				246				-
			22,807				(12,834	)			(7,307	)
Changes in operating asset and liability items:
Decrease (increase) in trade receivables			(358	)			(2,118	)			2,430
Decrease (increase) in inventory			(1,953	)			(1,192	)			997
Decrease (increase) in prepaid expenses and other receivables			(959	)			(43	)			1,310
Increase (decrease) in accounts payable and accruals			5,512				(5,508	)			(3,478	)
Increase (decrease) in contract liabilities			12,957				(12,957	)			-
			15,199				(21,818	)			1,259
			38,006				(34,652	)			(6,048	)

Supplemental information on interest received in cash			2,020				1,992				1,153
Supplemental information on interest paid in cash			1,111				10,387				1,268

Supplemental information on non-cash transactions:
Changes in right-of-use asset and lease liabilities			149				327				(57	)
Fair value of exercised warrants (portion related to accumulated fair value adjustments)			3,631				-				-
Intangible asset acquired in connection with GLIX1 collaboration transaction			-				-				6,000

FAQ

How did BioLineRx (BLRX) perform financially in 2025?

BioLineRx reported total revenues of $1,180 thousand in 2025, down from $28,940 thousand in 2024. Loss attributable to owners narrowed significantly to $1,175 thousand, compared with a $9,221 thousand loss in 2024, as operating losses fell and non‑operating income increased.

What is the status of BioLineRx’s GLIX1 program as of the 2025 results?

BioLineRx plans to start a Phase 1/2a first‑in‑human trial of GLIX1 in glioblastoma by the end of March 2026. GLIX1 is a first‑in‑class oral small molecule targeting DNA damage response, with strong preclinical efficacy, blood‑brain‑barrier penetration and favorable toxicology data.

What clinical progress has BioLineRx (BLRX) made with motixafortide?

BioLineRx continues the CheMo4METPANC Phase 2b trial of motixafortide in metastatic pancreatic cancer, led by Columbia University with Regeneron support. Enrollment has accelerated, and a prespecified interim or futility analysis is anticipated in 2026, complementing the approved APHEXDA indication in multiple myeloma transplantation.

What does BioLineRx’s balance sheet look like at December 31, 2025?

At December 31, 2025, BioLineRx held $3,250 thousand in cash and cash equivalents and $17,626 thousand in short‑term deposits. Total assets were $40,905 thousand, total liabilities $17,560 thousand, and total equity $23,345 thousand, including a $6,000 thousand GLIX1 intangible asset.

How did BioLineRx’s operating performance change between 2024 and 2025?

Operating loss improved from $20,408 thousand in 2024 to $10,287 thousand in 2025, while loss and comprehensive loss fell to $2,026 thousand. This reflects lower research and development and general and administrative expenses, along with meaningful non‑operating income during 2025.

What were BioLineRx’s cash flow trends in 2025?

In 2025, BioLineRx used $8,074 thousand in operating cash flows and $8,545 thousand in investing activities, mainly from short‑term deposit movements. Financing activities provided $8,884 thousand, primarily from equity and warrant issuance, leading to a net decrease of $7,735 thousand in cash and cash equivalents.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99 PRESS RELEASE 489.1 KB